Compare FirstEnergy Corp. (FE) vs GSK plc (GSK) Price & Performance

FirstEnergy (FE) trades at $46.76, down 1.5% with bearish technical signals despite recent earnings beat. The utility shows steady revenue growth to $15.09B (2025) and maintains a 6.86% net margin, though EPS performance has been mixed. Analyst consensus is divided with 12 Buy and 16 Hold ratings, targeting $52.67 average price. Recent news highlights institutional buying and grid investments to support rising data center demand.

Investment outlook balances growth from infrastructure spending and data center demand against execution risks and debt levels. The stock offers value below analyst targets with dividend income, but faces headwinds from capital expenditure requirements and interest rate sensitivity. Current valuation at P/E 25.05 appears reasonable for sector growth prospects.

GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.

Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.